Skip to main content

STRATA Skin Sciences, Inc.

corporate_fare Company Profile

STRATA Skin Sciences, Inc.

SSKN·OTC·Healthcare·CIK 0001051514

STRATA Skin Sciences, Inc. is a medical technology company that develops, commercializes, and markets innovative products for treating dermatologic conditions. The company's product portfolio includes the XTRAC® line of excimer lasers and VTRAC® lamp systems, which are used to treat psoriasis, vitiligo, and other skin conditions. Additionally, STRATA Skin Sciences offers the TheraClear® X Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The Pharos device is no longer available. The company was incorporated in New York in 1989 as Electro-Optical Sciences, Inc., reincorporated in Delaware in 1997, and changed its name to MELA Sciences, Inc. in April 2010. In June 2015, the company acquired the XTRAC® excimer laser and VTRAC® excimer lamp businesses from PhotoMedex, Inc. Prior to this acquisition, its sole product was the MelaFind® system, which aided dermatologists in evaluating atypical pigmented skin lesions. On January 5, 2016, the company changed its name to STRATA Skin Sciences, Inc. and discontinued the MelaFind business. In August 2021 and January 2022, the company acquired the Pharos U.S. dermatology business and the TheraClear acne treatment business, respectively. The Pharos line was discontinued concurrently with its acquisition, with service and support for Pharos laser system products provided through the expiration of extended warranty service contracts in 2024.

STRATA Skin Sciences, Inc. (OTC:SSKN) is a publicly traded company in the Healthcare sector. Wiseek monitors SSKN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • STRATA Skin Sciences Faces Going Concern Doubt After Nasdaq Delisting, Debt Default, and Massive Tax Liabilities
  • STRATA Skin Sciences to be Delisted from Nasdaq, Plans to Go Dark

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$30.7M
Net Income
-$6.26M
Diluted EPS
-$1.35
Op. Cash Flow
-$2.79M
Free Cash Flow
-$4.26M
Gross Profit
$17.88M
Operating Income
-$4.7M
Cash & Equivalents
$7.91M
Total Debt
$15.35M
Debt / Equity
5.28×
Net Margin
-20.4%
Shares Outstanding
5.89M sh
Source: 10-K · filed 2026-03-26 · accession 0001140361-26-011231
Browse all tickers starting with S →
$0.121
52-week range · as of 2026-03-26 $0.1202 – $3.86
Market cap
$712.47K
Volume
10.7K (0.6× avg)
3-mo avg 19.4K
Live data · 2026-06-14 06:07 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SSKN - Latest Insights

SSKN
Mar 25, 2026, 9:33 PM EDT
Filing Type: 10-K
Importance Score:
10
Price at Filing: $0.245
Real-time Price: $0.121 info
Change: -$0.124 (-51%) info
Market Cap: $712.472K info
SSKN
Feb 11, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
10
Price at Filing: $0.7135
Real-time Price: $0.121 info
Change: -$0.5925 (-83%) info
Market Cap: $712.472K info